Skip to main content
Premium Trial:

Request an Annual Quote

23andMe Closes on $22M Series C Funding

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – 23andMe today said that it has closed on its Series C financing, raising more than $22 million.

New investor Johnson & Johnson Development Corp. participated in the round, which also included New Enterprise Associates and Google Ventures, the Mountain View, Calif.-based personal genetics testing firm said in a statement.

"We believe this round of financing will help us achieve our goal of dramatically accelerating the pace of research and could ultimately make healthcare research and healthcare delivery more efficient," Anne Wojcicki, CEO of 23andMe, said in a statement.

In June last year, the company received $2.6 million in a Series B investment from Google. It also invested $3.9 million into 23andMe in 2007 to help the company launch.

In addition, 23andMe said that it has a number of key positions open that it is looking to fill. A year ago, the firm laid off staff in response to the economy and to remain competitive.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.